AxoGen, Inc. (0HKD.L)
- GlobeNewswire
Axogen, Inc Reports First Quarter 2024 Financial Results
ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2024. First Quarter Financial Results First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023.In the first quarter of 2024, our gross margin increased to 78.8%, up fro
- Simply Wall St.
AxoGen, Inc. (NASDAQ:AXGN) is largely controlled by institutional shareholders who own 58% of the company
Key Insights Institutions' substantial holdings in AxoGen implies that they have significant influence over the...
- GlobeNewswire
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
ALACHUA, Fla. and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™. “We are excited to expand our offering in nerve protection with the introduction of this resorbable barrier to support the critical phases of healing for nerve injuries,” said Karen Zaderej, chairman, CEO,
